注射用灯盏花素脂质体在Beagle犬体内的药代动力学

目的制备灯盏花素脂质体，研究灯盏花素脂质体在Beagle犬体内的药代动力学。方法采用双周期交叉试验法，6只Beagle犬分别单剂量(以灯盏乙素计为28 mg/只)静脉注射自制灯盏花素脂质体和市售普通注射液，用反相高效液相色谱法测定不同时间血浆中灯盏乙素的浓度，采用3P97计算药代动力学参数，并进行统计学分析。结果脂质体和市售注射液的T_1/2α分别为(4.4±0.7) min和(1.8±1.3) min；T_1/2<>分别为(55±27) min和(28±23) min；V_c分别为(1 580±265) mL和(2 460±2 200) mL；CL_s分别为(88±10) mL·min^-1和(324±69) mL·min^-1； AUC_0-720分别为(363±42) μg·min·mL^-1和(102±19) μg·min·mL^-1。两种制剂的T_1/2α，CL_s及AUC_0-720经方差分析后均存在极显著或显著性差异。结论与市售普通注射液相比，灯盏花素脂质体Beagle犬静脉注射给药后，大大提高了血药浓度，显著改善了灯盏乙素原药的药代动力学性质，具有缓释作用。

Pharmacokinetics of breviscapine liposomes following intravenous injection in Beagle dogs

AIM: To prepare the breviscapine liposomes and study the pharmacokinetics of breviscapine liposomes in Beagle dogs. METHODS: The cross-over design (two periods) was employed. Six Beagle dogs were administrated a single intravenous dosage of 28 mg of breviscapine liposomes and reference preparation, respectively, scutellarin in plasma of 6 dogs at different sampling time was determined by RP-HPLC. The pharmacokinetic parameters were calculated by 3P97 program and compared by statistic analysis. RESULTS: The mean concentration-time curves of breviscapine liposomes and reference preparation were both fitted to two-compartment model with the main pharmacokinetic parameters as follows: T 1/2 alpha were (4.4 +/- 0.7) min and (1.8 +/- 1.3) min respectively; T 1/2 beta were (55 +/- 27) min and (28 +/- 23) min respectively; V(c) were (1 580 +/- 265) mL and (2 460 +/- 2 200) mL respectively; CL(s) were (88 +/- 10) mL x min(-1) and (324 +/- 69) mL x min(-1) respectively; and AUC(0-720) were (363 +/- 42) microg x min x mL(-1) and (102 +/- 19) microg x min x mL(-1) respectively. The T 1/2 alpha, CL(s) and AUC(0-720) of breviscapine liposomes all had significant difference from those of reference preparation, after the data were examined by a one-way analysis of variance (ANOVA). CONCLUSION: Compared with the reference preparation, breviscapine liposomes had a much more higher concentration in plasma and contained characteristic of sustained-release, which ameliorated the pharmacokinetic properties of scutellarin.